Interstitial and orphan lung disease

Pharmacotherapy for lung cancer with comorbid interstitial pneumonia: limited evidence requires appropriate evaluation
Yuriko Ishida, Satoshi Ikeda, Akimasa Sekine, Tomohisa Baba, Takashi Ogura

ERJ Open Research Oct 2022, 8 (4) 00337-2022; DOI: 10.1183/23120541.00337-2022
Effect of nintedanib on acute exacerbations of fibrosing interstitial lung diseases: a national database study in Japan
Hirokazu Urushiyama, Taisuke Jo, Wakae Hasegawa, Akira Yokoyama, Takahiro Ando, Yukiyo Sakamoto, Ryosuke Kumazawa, Kazuaki Uda, Nobuaki Michihata, Nobuyasu Awano, Matsui Hiroki, Kiyohide Fushimi, Hideo Yasunaga, Takahide Nagase

ERJ Open Research Oct 2022, 8 (4) 00209-2022; DOI: 10.1183/23120541.00209-2022
Pulmonary hypertension in interstitial lung disease: an area of unmet clinical need
Sebastiaan Dhont, Bert Zwaenepoel, Els Vandecasteele, Guy Brusselle, Michel De Pauw

ERJ Open Research Oct 2022, 8 (4) 00272-2022; DOI: 10.1183/23120541.00272-2022
Analysis of real-world data and a mouse model indicates that pirfenidone causes pellagra
Koji Kuronuma, Natsumi Susai, Tomohiro Kuroita, Hiroki Yamamoto, Takeshi Yoshioka, Shuji Kaneko, Hirofumi Chiba

ERJ Open Research Oct 2022, 8 (4) 00245-2022; DOI: 10.1183/23120541.00245-2022
Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis
Toby M. Maher, Christina Schlecker, Doreen Luedtke, Sebastian Bossert, Donald F. Zoz, Armin Schultz

ERJ Open Research Oct 2022, 8 (4) 00240-2022; DOI: 10.1183/23120541.00240-2022
Matrix metalloproteinase-7 is increased in lung bases but not apices in idiopathic pulmonary fibrosis
Jade Jaffar, Mae Wong, Gregory A. Fishbein, Monther Alhamdoosh, Laura McMillan, Cristina Gamell-Fulla, Milica Ng, Nick Wilson, Karen Symons, Ian Glaspole, Glen Westall

ERJ Open Research Oct 2022, 8 (4) 00191-2022; DOI: 10.1183/23120541.00191-2022
Neighbourhood disadvantage impacts on pulmonary function in patients with sarcoidosis
Gillian C. Goobie, Christopher J. Ryerson, Kerri A. Johannson, Spencer Keil, Erin Schikowski, Nasreen Khalil, Veronica Marcoux, Deborah Assayag, Hélène Manganas, Jolene H. Fisher, Martin R.J. Kolb, Xiaoping Chen, Kevin F. Gibson, Daniel J. Kass, Yingze Zhang, Kathleen O. Lindell, S. Mehdi Nouraie

ERJ Open Research Oct 2022, 8 (4) 00357-2022; DOI: 10.1183/23120541.00357-2022
Functional clinical impairments and frailty in interstitial lung disease patients
Pierre-François Tremblay Labrecque, Geneviève Dion, Didier Saey

ERJ Open Research Oct 2022, 8 (4) 00144-2022; DOI: 10.1183/23120541.00144-2022
Corticosteroid-induced remission and mycophenolate maintenance therapy in granulomatous lymphocytic interstitial lung disease: long-term, longitudinal change in lung function in a single-centre cohort
Heba M. Bintalib, David M. Lowe, Gaia Mancuso, Georgia Gkrepi, Suranjith L. Seneviratne, Siobhan O. Burns, John R. Hurst

ERJ Open Research Oct 2022, 8 (4) 00024-2022; DOI: 10.1183/23120541.00024-2022
Two cases of nintedanib-induced diarrhoea treated using a 5-hydroxytryptamine type 3 receptor antagonist
Toru Arai, Yoshikazu Inoue

ERJ Open Research Jul 2022, 8 (3) 00242-2022; DOI: 10.1183/23120541.00242-2022

Main menu

User menu

Search

Interstitial and orphan lung disease

Pages

Contact us